Amino Acids
1 Taurine
Rationale. Taurine is a conditionally essential amino acid found in high concentrations in skeletal muscle, heart, and the nervous system. It has multiple roles relevant to ME/CFS pathophysiology:
- Na+/K+-ATPase support: Taurine depletion impairs Na+/K+-ATPase function; conversely, supplemental taurine may help maintain pump activity—potentially intersecting the AIMM cascade at the step immediately upstream of sodium-calcium exchanger (NCX) reversal via an analogous mechanism (demonstrated in macrophages, not yet in skeletal muscle) (see Section:calcium-dysregulation in Chapter:energy-metabolism)
- Mitochondrial membrane stabilization and calcium buffering: Taurine reduces pathological calcium accumulation, blocks endoplasmic reticulum stress, reduces mitochondrial permeability transition pore (mPTP) opening probability, and helps preserve mitochondrial membrane integrity during calcium overload
- NCX cascade position: In the AIMM model, the sequence is: hypoperfusion → acidosis → NHE1 imports Na+ → Na+/K+-ATPase overloaded → NCX reversal → Ca2+ overload → mitochondrial damage → PEM. Taurine acts at two nodes: upstream (pump support) and downstream (calcium buffering)
- Disturbed pathway in ME/CFS: Taurine metabolism has been identified as a top-ranked disturbed metabolic pathway in ME/CFS plasma metabolomics in one exploratory study (n=17); pathway rankings from untargeted metabolomics in small cohorts are exploratory and database-dependent. Impaired taurine pathway recovery has also been observed during the post-exertional window These findings identify taurine as a mechanistically plausible target but do not establish plasma depletion or clinical benefit from supplementation
- Antioxidant and osmolyte functions: Taurine acts as an osmolyte supporting cell volume regulation and has antioxidant properties relevant to oxidative stress documented in ME/CFS
Evidence.
Germain et al. (2017) profiled plasma metabolomics in 17 ME/CFS patients versus 15 controls and identified taurine and taurine-conjugate metabolism as the top-ranked disturbed metabolic pathway, ahead of glycerophospholipid metabolism and bile acid biosynthesis Glass et al. (2023) found impaired taurine pathway recovery during the post-exertional window in a small pilot (n=10 ME/CFS, n=8 controls) using urine metabolomics
Limitations: Both studies are small (n ≤ 17), limited to metabolomics pathway analysis, and do not measure plasma taurine concentrations directly. Neither establishes whether supplementation would correct the disturbed pathway or produce clinical benefit. These findings support mechanistic plausibility, not clinical efficacy. Replication status: not yet replicated (single study each).
Certainty: 0.30. No direct taurine supplementation trial in ME/CFS exists. Rationale extrapolated from mechanistic analogs (cardiac, neurological), one recent Na+/K+-ATPase study, and classic cardiology framework
In cardiac and neurological contexts, taurine depletion impairs Na+/K+-ATPase function and allows NCX reversal-driven calcium overload Rossi-Smith et al. (2025) demonstrated this pathway in macrophages: intracellular taurine depletion via VRAC efflux → Na+/K+-ATPase failure → ionic dysregulation → NLRP3 inflammasome activation This molecular mechanism maps directly onto the AIMM Na+/K+-ATPase node.
Null result caveat: Marcangeli et al. (2025) found no association between serum taurine levels and age, muscle mass, mitochondrial respiration, or calcium handling in 137 men aged 20–93 —directly challenging the hypothesis that serum taurine reflects intracellular taurine status or predicts mitochondrial outcomes. An important limitation: the study measured serum taurine, not intracellular or tissue taurine; compartment-specific depletion could be present despite normal serum levels. Crucially, the compartment argument cuts both ways: if serum does not reflect intracellular taurine, then the Germain 2017 plasma metabolomics finding also cannot establish intracellular taurine depletion—both lines of evidence are limited to the same plasma compartment.
Critical counter-evidence: The strongest clinical analog—a systematic review of 11 taurine RCTs in heart failure (the condition sharing exercise intolerance and the proposed NCX/calcium overload cascade in cardiomyocytes)—showed non-significant effects on ejection fraction and stroke volume This null result should be the primary anchor for evaluating the ME/CFS hypothesis, not a cautionary note isolated elsewhere.
Falsifiable prediction: Taurine supplementation (1–2 g/day for 12 weeks) would improve post-exertional sodium accumulation measured by sodium MRI or reduce PEM severity in patients with documented intracellular sodium overload. Null result in patients without intracellular sodium overload would be consistent with the absence of mechanism.
Despite strong mechanistic rationale and disturbed metabolomic signals, no randomized controlled trial of taurine supplementation in ME/CFS has been published. The strongest analog evidence—a 2022 systematic review of taurine in heart failure (11 studies)—found non-significant effects on ejection fraction and stroke volume One small RCT in exercise-intolerant heart failure patients (n ≈ 30, 1,500 mg/day for 2 weeks) showed significant reductions in inflammatory markers but did not measure functional capacity or fatigue. Strong mechanistic rationale does not guarantee clinical benefit.
Forms.
- Pure L-taurine powder: Pharmaceutical or food grade; no bioactive isomers. Reputable brands (NOW Foods, Jarrow, Thorne, bulk suppliers) are equivalent; no evidence any proprietary form outperforms
- Magnesium taurate: Taurine chelated with magnesium; may benefit patients needing both (see Section:electrolytes); lower elemental taurine per dose than pure taurine
- Avoid combined formulas with stimulants: Energy drink and pre-workout formulations conflict with ME/CFS pacing requirements
Dosing.
- Research-analog doses: 1,000–3,000 mg daily, typically split (500 mg–1,000 mg twice daily)
- ME/CFS starting dose: 500 mg/day for 1–2 weeks; titrate slowly—taurine shifts osmolyte balance and may transiently alter electrolyte handling
- Maintenance: 1,000–2,000 mg daily if tolerated
- Take with meals to reduce gastrointestinal side effects
Timing. No established protocol specific to ME/CFS. For the AIMM hypothesis (preventing exertion-triggered NCX cascade), pre-exertional dosing has theoretical support but is unstudied.
Response Timeline. Unknown in ME/CFS. Cardiac analogs suggest 2–4 weeks minimum. Allow 8–12 weeks before concluding non-response.
What to track.
- PEM frequency and severity (primary target if AIMM mechanism active)
- Muscle pain or weakness changes
- Any symptom shift in first 2–3 weeks at each dose step; keep a symptom diary
Cautions. Generally well-tolerated. Mild gastrointestinal discomfort possible; start low. May transiently shift electrolyte balance in patients with marginal Na+/K+-ATPase function (see:taurine-aimm for mechanistic basis; extrapolation from preclinical evidence).
Both taurine (targeting the AIMM/NCX cascade via Na+/K+-ATPase support) and low-dose naltrexone address calcium dysregulation in ME/CFS. LDN has four mechanisms with non-overlapping dose optima — TLR4/Nrf2 hormetic priming (0.5–1.5 mg), opioid compensatory upregulation (1.5–3.0 mg), TRPM3 restoration (3.0–4.5 mg), and orexin disinhibition — which of these is active depends on the patient’s optimal dose (hormetic dose response). Taurine’s AIMM/NCX node is mechanistically complementary to TRPM3-dominant LDN response (both address calcium dysregulation), but speculative for TLR4-dominant or opioid-dominant responses. However, all pathway attributions are at speculation level (certainty ≤ 0.30). Whether either pathway is active in a given patient is unconfirmed. The claim that they are “mechanistically complementary” rests on two separate unvalidated hypotheses. No clinical evidence for this combination exists. No pharmacological interaction between taurine and LDN is expected, but combined use should be discussed with a physician.
Energy Profile. Category A–B (provider to neutral). Acts at two nodes of the AIMM cascade: upstream (Na+/K+-ATPase maintenance) and downstream (calcium buffering, mitochondrial membrane stabilization). Functions as an osmolyte with minimal ATP cost. May improve mitochondrial efficiency without direct ATP provision. Clinical energy benefit in ME/CFS is unproven.
Certainty: 0.20. Speculative. No ME/CFS study has directly measured taurine partitioning between bile acid conjugation and intracellular pools. Taurine direction in the disturbed Germain 2017 pathway is not specified.
Taurine is consumed by two major competing pathways: (1) hepatic bile acid conjugation (taurocholate, taurodeoxycholate) and (2) intracellular cytoprotective roles (osmolyte, calcium buffer, Na+/K+-ATPase support). Germain et al. (2017) found both taurine metabolism and bile acid biosynthesis ranked among the top disturbed metabolic pathways in ME/CFS plasma These are not independent signals: taurine IS a bile acid conjugation substrate. If ME/CFS gut dysbiosis (see Chapter:gut-microbiome) drives increased enterohepatic cycling or impaired bile acid reabsorption, hepatic taurine demand rises, diverting taurine away from muscle and immune cell cytoprotection — including the Na+/K+-ATPase support role at the AIMM cascade node. Co-supplementing glycine (2–3 g/day), which is an alternative bile acid conjugation substrate, may spare taurine for intracellular functions by competing for the hepatic conjugation pathway.
Falsifiable prediction: (a) ME/CFS patients show a higher taurine-conjugated to glycine-conjugated bile acid ratio than controls. (b) Glycine co-supplementation raises free plasma taurine more than equivalent taurine supplementation alone.
The Marcangeli et al. (2025) null result—no association between serum taurine and muscle mass, mitochondrial respiration, or calcium handling in 137 humans —challenges assuming that serum taurine reflects intracellular taurine status. Red blood cell (RBC) taurine concentration provides a more direct intracellular proxy: RBCs have Na+/K+-ATPase and taurine transport, making them an accessible cellular model for the ionic mechanism. Whether ME/CFS patients have lower RBC taurine despite normal serum taurine has not been measured.
A second open question: does baseline taurine status predict the magnitude of post-exertional physiological dysfunction? Adding pre-CPET plasma or RBC taurine measurement to the standard two-day CPET protocol would allow stratification of the Day 2 decrement by taurine status. If taurine-depleted patients show a larger Day 2 decrement, this would identify a treatment-responsive AIMM subgroup.
Combination note: taurine in the ionic resilience stack. For patients in whom the AIMM cascade is suspected (significant exertion-triggered PEM, documented orthostatic intolerance, intracellular sodium accumulation if tested by sodium MRI), taurine combines rationally with its ionic support partners: magnesium (cofactor for Mg-ATP, the true Na+/K+-ATPase substrate), and potassium (the pump’s import substrate). All three support Na+/K+-ATPase function at different molecular points. For practical dosing of this combination, see Section:electrolytes (magnesium, potassium) and this section.
Certainty: 0.30. Taurine acts as a GABA-A receptor agonist and reduces extracellular glutamate via volume-regulated anion channels. Lowers glutamatergic tone; improves mitochondrial calcium handling. 500-2000mg/day. No ME/CFS data.
Falsifiable prediction. 8 weeks taurine 1g BID reduces cognitive fatigue only in high Glu-PRS subgroup.
2 Glycine
Rationale.
- Glutathione precursor (with NAC)
- Inhibitory neurotransmitter (calming)
- Supports collagen synthesis
- May improve sleep quality
Dosing. 1–3 g daily; 3 g before bed for sleep.
Energy Profile. Category A–B (provider to neutral). Glycine is one of three glutathione precursors (alongside cysteine and glutamate; NAC is typically rate-limiting for cysteine availability), supporting mitochondrial protection from oxidative damage. Also serves as a conjugation substrate for Phase II hepatic detoxification (glycine N-acyltransferase), potentially reducing the metabolic burden of processing other supplements. Minimal processing cost as an endogenous amino acid.
3 L-Glutamine
Rationale.
- Gut barrier support
- Immune cell fuel
- Glutathione precursor
Dosing. 5–15 g daily for gut support.
Cautions. Some patients with neurological sensitivity may not tolerate glutamine (converts to glutamate).
Energy Profile. Category A–B (provider to neutral). Primary fuel for enterocytes (intestinal cells) and immune cells. Provides energy substrate for gut barrier maintenance, potentially reducing the energy cost of intestinal permeability and immune activation from microbial translocation. Also serves as gluconeogenic substrate when glucose is depleted.
Certainty: 0.30. L-theanine structurally resembles glutamate and competes for glutamate transporters, reducing synaptic glutamate concentrations. Also increases GABA, serotonin, and dopamine in brain. Crosses BBB. 200-400mg/day, well-tolerated with minimal side effects, low cost. No ME/CFS data.
Falsifiable prediction. 4 weeks theanine 200mg BID reduces subjective sensory hypersensitivity only in high Glu-PRS subgroup.
4 5-HTP (5-Hydroxytryptophan)
Rationale. 5-HTP is the immediate precursor to serotonin, produced from tryptophan by tryptophan hydroxylase. Supplementing with 5-HTP bypasses the IDO2 (and IDO1) diversion point (Wirth and Scheibenbogen 2025): in ME/CFS, IDO2 is the primary enzyme shunting tryptophan into the kynurenine pathway rather than toward serotonin synthesis (Phair, Davis, and Kashi 2019). Because 5-HTP is not a substrate for IDO enzymes, it directly enters the serotonin synthesis pathway regardless of IDO activity. In the gut, enterochromaffin cells convert 5-HTP to serotonin, which signals through vagal afferents to regulate autonomic tone (Barton et al. 2025). Supplemental 5-HTP may therefore partially compensate for impaired peripheral serotonin synthesis in ME/CFS patients with gut dysbiosis.
Evidence. Theoretical for ME/CFS-specific gut-vagal pathway; limited direct trial evidence. Best supported by mechanistic extrapolation from IDO2 pathway research in Long COVID and the enterochromaffin-vagal model (Wirth and Scheibenbogen 2025).
Dosing. 50–100 mg two to three times daily. Start at 50 mg once daily and titrate slowly. Requires adequate P5P (Section B Vitamins) as cofactor for the decarboxylase step.
Cautions.
- Serotonin syndrome: Contraindicated with SSRIs, SNRIs, MAOIs, tramadol, triptans (sumatriptan, rizatriptan, and other 5-HT1 agonists used for migraine — a common ME/CFS comorbidity), or other serotonergic drugs. This is a serious risk—medical supervision required if on any of these medications.
- Peripheral decarboxylation can cause systemic serotonin effects (GI cramping, nausea, diarrhea) before central effects appear.
- Avoid in pregnancy.
- Start very low if histamine-sensitive (serotonin can release histamine).
Energy Profile. Category B–C (neutral to mildly demanding). Conversion to serotonin via aromatic L-amino acid decarboxylase requires pyridoxal phosphate (vitamin B6) cofactor. The serotonin synthesis pathway itself is not particularly energy-intensive, but serotonergic effects can trigger mast cell activation in susceptible patients (MCAS comorbidity), and immune activation is energy-costly. Caution: serotonin syndrome risk with SSRIs represents a potentially catastrophic energy crisis.